CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Chimeric antigen receptor T cell immunotherapy for gynecological malignancies.
Chimeric antigen receptor T cell immunotherapy for gynecological malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
妇科恶性肿瘤对全球女性健康构成严重威胁。尽管免疫疗法已显著革新了肿瘤治疗策略,但复发性或晚期妇科恶性肿瘤的有效治疗选择仍然匮乏,给临床治疗带来了重大挑战。嵌合抗原受体(CAR)T细胞疗法在治疗血液系统恶性肿瘤方面已取得显著疗效,标志着肿瘤治疗模式的重大变革。然而,尽管近年来用于治疗实体瘤的CAR-T 细胞疗法逐渐增多,其在妇科恶性肿瘤中的疗效仍需进一步验证。本综述将深入探讨CAR-T 细胞工程及其针对妇科恶性肿瘤相关特定抗原的作用机制,系统评估CAR-T 细胞疗法在妇科肿瘤中的当前应用及临床试验进展,并讨论重大挑战及相应策略,从而为该领域的未来研究提供科学依据和指导。
Gynecologic malignancies pose a serious threat to women's health worldwide. Although immunotherapy has significantly revolutionized cancer treatment strategies, effective therapeutic options for recurrent or advanced gynecologic malignancies are still deficient, posing significant challenges to clinical therapy. Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable efficacy in treating hematologic malignancies, marking a significant change in the oncology treatment paradigm.
However, despite the gradual increase in CAR T cell therapy used in treating solid tumors in recent years, its efficacy in treating gynecologic malignancies still needs further validation.
This review will thoroughly examine CAR-T cell engineering and its mechanism of action on specific antigens associated with gynecologic malignancies, systematically assess the current application of CAR T cell therapy in gynecologic tumors and the advancements in clinical trials, and discuss the significant challenges and corresponding strategies, thereby offering a scientific foundation and guidance for future research in this area.
MEMBER ACCOUNT
登录成功会直接打开下一页。